New perspectives in the topical delivery of optimized amphotericin B loaded nanoemulsions using excipients with innate anti-fungal activities: A mechanistic and histopathological investigation

Nanomedicine: Nanotechnology, Biology, and Medicine

Volumn 13, Issue 3, 2017, Pages 1117-1126

  Hussain, Afzal ^a,b   Singh, Sima ^a   Webster, Thomas J ^c   Ahmad, Farhan Jalees ^d  

^a BIRLA INSTITUTE OF TECHNOLOGY   (India)

^b S Sinha College   (India)

^c Northeastern University   (United States)

^d HAMDARD UNIVERSITY   (India)

Author keywords

Enhanced flux; Fungal infections; Histopathology; Nanoemulsion; Topical delivery

Indexed keywords

BIOCOMPATIBILITY; PARTICLE SIZE; SCANNING ELECTRON MICROSCOPY; TITRATION;

ANTI-FUNGAL ACTIVITY; FUNGAL INFECTION; HISTOPATHOLOGY; NANOEMULSION; POLYDISPERSITY INDICES; SUSTAINED RELEASE; TOPICAL DELIVERY; ZONE OF INHIBITIONS;

FUNGI;

AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; CAPMUL MCM C8; CAPMUL PG8; CAPTEX 355P; CREMOPHOR; LABRASOL; MIGLYOL 829; PECEOL; POLYSORBATE 80; PROPYLENE GLYCOL; SURFACTANT; UNCLASSIFIED DRUG; ANTIFUNGAL AGENT; EMULSION; EXCIPIENT;

ANIMAL TISSUE; ANTIFUNGAL ACTIVITY; ARTICLE; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CONTROLLED STUDY; DISPERSITY; DRUG DELIVERY SYSTEM; DRUG MECHANISM; DRUG SOLUTION; EX VIVO STUDY; FUNGAL STRAIN; HEMOLYSIS; HISTOPATHOLOGY; IN VIVO STUDY; INHIBITION ZONE; NANOEMULSION; NANOFABRICATION; NONHUMAN; PARTICLE SIZE; RAT; SCANNING ELECTRON MICROSCOPY; SUSTAINED DRUG RELEASE; TITRIMETRY; ZETA POTENTIAL; ANIMAL; ASPERGILLOSIS; CANDIDIASIS; CHEMISTRY; CUTANEOUS DRUG ADMINISTRATION; DRUG EFFECTS; EMULSION; HUMAN; SKIN; SKIN ABSORPTION; ULTRASTRUCTURE;

ADMINISTRATION, CUTANEOUS; AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; CANDIDIASIS; EMULSIONS; EXCIPIENTS; HUMANS; RATS; SKIN; SKIN ABSORPTION;

EID: 85013641763     PISSN: 15499634     EISSN: 15499642     Source Type: Journal    
DOI: 10.1016/j.nano.2016.12.002     Document Type: Article

References (29)

1. 1 Kleinberg, M., What is the current and future status of conventional amphotericin B?. Int J Antimicrob Agents 27S (2006), S12–S16.
2. 2 Nahar, M., Mishra, D., Dubey, V., Jain, N.K., Development, characterization and toxicity evaluation of amphotericin B-loaded nanogelatin nanoparticles. Nanomedicine: Nanotechnology Biology and. Medicine 4 (2008), 252–261.
3. 3 Wong-Beringer, A., Jacobs, R.A., Guglielmo, B.J., Lipid formulations of amphotericin B: clinical efficacy and toxicities. Clin Infect Dis 27 (1998), 603–618.
4. 4 Espuelas, M.S., Legrand, P., Irache, J.M., Gamazo, C., Orecchioni, A.M., Devissaguet, J.P., et al. Poly(ε-caprolacton) nanospheres as an alternative way to reduce amphotericin B toxicity. Int J Pharm 158 (1997), 19–27.
5. 5 Hussain, A., Samad, A., Nazish, I., Ahmed, F.J., Nanocarrier-based topical drug delivery for an antifungal drug. Drug Dev Ind Pharm 40:4 (2013), 527–541.
6. 6 Glavas-Dodov, M., Fredro-Kumbaradzi, E., Goracinova, K., Simonoska, M., Calis, S., Trajkovic-Jolevska, S., et al. The effects of lyophilization on the stability of liposomes containing 5-FU. Int J Pharm 291 (2005), 79–86.
7. 7 Ahmed, M., Ramadan, W., Rambhu, D., Shakeel, F., Potential of nanoemulsions for intravenous delivery of rifampicin. Die Pharm 63 (2008), 806–811.
8. 8 Hussain, A., Samad, A., Singh, S.K., Ahsan, M.N., Faruk, A., Ahmed, F.J., Enhanced stability and permeation potential of nanoemulsion containing sefsol-218 oil for topical delivery of amphotericin B. Drug Dev Ind Pharm 41:5 (2014), 780–790.
9. 9 Hussain, A., Samad, A., Singh, S.K., Ahsan, M.N., Faruk, A., Ahmed, F.J., Nanoemulsion gel-based topical delivery of an antifungal drug: in vitro activity and in vivo evaluation. Drug Deliv 33:2 (2014), 642–647.
10. 10 Hussain, A., Singh, V.K., Singh, O.P., Shafaat, K., Kumar, S., Ahmad, F.J., Formulation and optimization of nanoemulsion using antifungal lipid and surfactant for accentuated topical delivery of amphotericin B. Drug Deliv Early Online, 1–10, 2016, 10.3109/10717544.2016.1153747.
11. 11 Singh, N., Verma, S.M., Singh, S.K., Verma, P.R.P., Evidence for bactericidal activities of lipidic nanoemulsions against Pseudomonas aeroginosa. Antonie Van Leeuwenhoek 107:6 (2015), 15555–15568.
12. 12 Kadimi, U.S., Balasubramanian, D.R., Ganni, U.R., Manohar, B.M., Govindarajulu, V., Vitro studies on liposomal amphotericin B obtained by supercritical carbon dioxide-mediated process. Nanomedicine: Nanotechnology Biology and. Medicine 3 (2007), 273–280.
13. 13 Azeem, A., Rizwan, M., Ahmad, F.J., Iqbal, Z., Khar, R.K., Aqil, M., et al. Nanoemulsion components screening and selection: a technical note. AAPS PharmSciTech 10:1 (2009), 69–76.
14. 14 Chang, S., Lin, S., Chen, T., Lin, Y., A biocide-free mineral oil nanoemulsion exhibiting strong bactericidal activity against Mycobacterium immunogenum and Pseudomonas aeruginosa. Int Biodeterioration Biodegradation 70 (2012), 66–73.
15. 15 Craig, D.Q.M., Barker, S.A., Banning, D., An investigation into the mechanisms of self-emulsification using particle size analysis and low frequency dielectric spectroscopy. Int J Pharm 114 (1995), 103–110.
16. 16 Freitas, C., Muller, R.H., Effect of light and temperature on zeta potential and physical stability in solid lipid nanoparticle (SLN) dispersions. Int J Pharm 168 (1998), 221–229.
17. 17 Hussain, A., Singh, S.K., Evidence for anti-mycobacterium activities of lipids and surfactants. World J Microbiol Biotechol, 32(1), 2016, 7 [(early online)] 10.1007/s11274-015-1965-4.
18. 18 Hoeprich, P.D., Clinical use of amphotericin B and derivatives: lore, mystique, and fact. Clin Infect Dis 14:1 (1992), S114–S119.
19. 19 Ouellette, M., Drummelsmith, J., et al. Leishmaniasis: drugs in the clinic, resistance and new developments. Drug Resist Updat 7:4 (2004), 257–266.
20. 20 Zhou, H., Yue, Y., Liu, G., Li, Y., Zhang, J., Gong, Q., et al. Preparation and characterization of a lecithin nanoemulsion as a topical delivery system. Nanoscale Res Lett 5 (2010), 224–230.
21. 21 Kotler-Brajtburg, J., Medoff, G., Kobayashi, G.S., Bogss, S., Sclessinger, D., Pandey, R., et al. Classification of polyene antibiotics according to chemical structure and biological effects. Antimicrob Agent Chemother 43 (1979), 267–271.
22. 22 Brajtburg, J., Medoff, G., Kobayashi, G.S., Elberg, S., Finegold, C., Permeabilizing and hemolytic action of large and small polyene antibiotics on human erythrocytes. Antimicrob Agents Chemother 18 (1980), 586–592.
23. 23 Singh, N., Verma, S.M., Singh, S.K., Verma, P.R.P., Ahsan, M.N., Antibacterial activity of cationised and non-cationised placebo lipidic nanoemulsion using transmission electron microscopy. J Exp Nanosci 10:4 (2015), 299–309.
24. 24 Filippin, F.B., Souza, L.C., Maranhão, R.C., Amphotericn B associated with triglyceride-rich nanoemulsion: stability studies and in vitro anti-fungal activities. Quím Nova 31:3 (2008), 591–594.
25. 25 Wasan, K.M., Morton, R.E., Rosenblum, M.G., Lopez-Berestein, G., Decreased toxicity of liposomal amphotericin B due to association of amphotericin B with high-density lipoproteins: role of lipid transfer protein. J Pharm Sci 83 (1994), 1006–1010.
26. 26 Wissing, S.A., Lippacher, A., Müller, R.H., Investigations on the occlusive properties of solid lipid nanoparticles (SLN). J Cosmet Sci 52 (2001), 313–323.
27. 27 Teichmann, A., Heuschkel, S., Jacobi, U., Presse, G., Neubert, R.H., Sterry, W., et al. Comparison of stratum corneum penetration and localization of a lipophilic model drug applied in an o/w microemulsion and an amphiphilic cream. Eur J Pharm Biopharm 67 (2007), 699–706.
28. 28 Fukui, H., Koike, T., Nakagawa, T., Saheki, A., Sonoke, S., Tomii, Y., et al. Comparison of LNS AmB, a novel low-dose formulation of amphotericin B with lipid nano-sphere (LNS®) with commercial lipid-based formulations. Int J Pharm 267 (2003), 101–112.
29. 29 Tanojo, H., Geest, A.B., Bouwstra, J.A., Junginger, H.E., Bodde, H.E., In vitro human skin barrier perturbation by oleic acid: thermal analysis and freeze fracture electron microscopy studies. Thermochemica Acta 293 (1997), 77–85.